Pharming Corp (PHAR) - Long-Term Debt to Capital Coefficient

The daily price chart for Pharming Group N.V. (PHAR) reflects the resilience of a company whose market power is based on the exclusive ownership of protein synthesis methods for treating rare pathologies. Business revenues remain independent of economic crises, as demand for life-saving therapy is stable. The current indicator stands at 0.35, while the R&D strategy relies on the systematic expansion of medical indications for existing drugs.

This ratio compares liabilities with a maturity of over one year to equity, measuring the proportion of debt financing within the balance sheet structure to assess long-term solvency. An optimal balance of this metric provides Pharming Group N.V. (PHAR) with the resources for expansion into targeted therapy niches for rare diseases, which determines the current level of long-term financial leverage.